Heterotrimerization of erbB3/erbB2/IGF-IR blocked trastuzumab binding and activated PI3K/AKT signaling pathway and Src kinase, which resulted in trastuzumab resistance in breast cancer cells[30]. Here, ERBB2 is linked to breast carcinoma.